277 related articles for article (PubMed ID: 2947818)
21. Response to intermittent RU486 in women.
Spitz IM; Croxatto HB; Salvatierra AM; Heikinheimo O
Fertil Steril; 1993 May; 59(5):971-5. PubMed ID: 8486197
[TBL] [Abstract][Full Text] [Related]
22. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
J Assist Reprod Genet; 1998 Nov; 15(10):599-604. PubMed ID: 9866068
[TBL] [Abstract][Full Text] [Related]
23. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
24. [Contraception by cyclic treatment with buserelin and progesterone].
Wieacker P; Breckwoldt M; Greif M; Geisthövel F
Geburtshilfe Frauenheilkd; 1991 Feb; 51(2):135-9. PubMed ID: 1904039
[TBL] [Abstract][Full Text] [Related]
25. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
Ruchhoft EA; Elkind-Hirsch KE; Malinak R
Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
[TBL] [Abstract][Full Text] [Related]
26. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol.
Wenzl R; Bennink HC; van Beek A; Spona J; Huber J
Fertil Steril; 1993 Oct; 60(4):616-9. PubMed ID: 8405513
[TBL] [Abstract][Full Text] [Related]
27. Comparison of ovarian follicular activity during treatment with a monthly injectable contraceptive and a low-dose oral contraceptive.
Jain JK; Ota F; Mishell DR
Contraception; 2000 Mar; 61(3):195-8. PubMed ID: 10827333
[TBL] [Abstract][Full Text] [Related]
28. Ovulation inhibition with nafarelin acetate nasal administration for six months.
Brenner PF; Shoupe D; Mishell DR
Contraception; 1985 Dec; 32(6):531-51. PubMed ID: 2936564
[TBL] [Abstract][Full Text] [Related]
29. Return of ovulation following a single injection of depo-medroxyprogesterone acetate: a pharmacokinetic and pharmacodynamic study.
Lan PT; Aedo AR; Landgren BM; Johannisson E; Diczfalusy E
Contraception; 1984 Jan; 29(1):1-18. PubMed ID: 6234145
[TBL] [Abstract][Full Text] [Related]
30. Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle-stimulating hormone in patients with polycystic ovarian disease.
Lanzone A; Fulghesu AM; Spina MA; Apa R; Menini E; Caruso A; Mancuso S
J Clin Endocrinol Metab; 1987 Dec; 65(6):1253-8. PubMed ID: 3119655
[TBL] [Abstract][Full Text] [Related]
31. Interference in follicular maturation following acute intranasal LH-RH agonist administration during mid and late follicular phase.
Lemay A; Faure N
Int J Fertil; 1988; 33(1):60-7. PubMed ID: 2896176
[TBL] [Abstract][Full Text] [Related]
32. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
Carlström K; Lunell NO; Zador G
Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
[TBL] [Abstract][Full Text] [Related]
33. Effects of chronic treatment with a gonadotrophin-releasing hormone agonist on peripheral concentrations of FSH and LH, and ovarian function in heifers.
Gong JG; Bramley TA; Gutierrez CG; Peters AR; Webb R
J Reprod Fertil; 1995 Nov; 105(2):263-70. PubMed ID: 8568770
[TBL] [Abstract][Full Text] [Related]
34. Intranasal LHRH agonist (Buserelin) after ovulation: a post-coital contraceptive approach.
Lemay A; Faure N; Labrie F; Fazekas AT
Contracept Deliv Syst; 1983 Apr; 4(2):107-25. PubMed ID: 12338631
[TBL] [Abstract][Full Text] [Related]
35. Programmed oocyte retrieval: clinical and biological effects of oral contraceptives administered before in vitro fertilization.
Mashiach S; Dor J; Goldenberg M; Shalev J; Levran D; Rudak E; Nebel L; Goldman B; Blankstein J; Ben-Rafael Z
Gynecol Endocrinol; 1989 Jun; 3(2):107-15. PubMed ID: 2816477
[TBL] [Abstract][Full Text] [Related]
36. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
[TBL] [Abstract][Full Text] [Related]
37. Gonadotropins and estradiol responses to single intranasal or subcutaneous administration of a luteinizing hormone-releasing hormone agonist in the early follicular phase.
Lemay A; Metha AE; Tolis G; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1983 May; 39(5):668-73. PubMed ID: 6404661
[TBL] [Abstract][Full Text] [Related]
38. Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.
Bergquist C; Nillius SJ; Wide L
Fertil Steril; 1982 Aug; 38(2):190-3. PubMed ID: 6809500
[TBL] [Abstract][Full Text] [Related]
39. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome.
Berga SL; Yen SS
Clin Endocrinol (Oxf); 1989 Feb; 30(2):177-84. PubMed ID: 2532984
[TBL] [Abstract][Full Text] [Related]
40. The response of the pituitary-ovarian axis to pulsatile administration of gonadotropin-releasing hormone in long-term oral contraceptive users.
Hemrika DJ; Slaats EH; Schoemaker J
Am J Obstet Gynecol; 1994 Feb; 170(2):462-8. PubMed ID: 8116698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
